References
- Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393(10167):169–182. doi:10.1016/S0140-6736(18)32470-X
- Abu-Rustum NR, Yashar CM, Bean S, et al. NCCN Guidelines Insights: cervical Cancer, Version 1.2020. J Natl Compr Canc Netw. 2020;18(6):660–666. doi:10.6004/jnccn.2020.0027
- Bhatla N, Singhal S, Dhamija E, et al. Implications of the revised cervical cancer FIGO staging system. Indian J Med Res. 2021;154(2):273–283. doi:10.4103/ijmr.IJMR_4225_20
- Wright JD, Matsuo K, Huang Y, et al. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019;134(1):49–57. doi:10.1097/AOG.0000000000003311
- Cursano MC, Kopf B, Scarpi E, et al. Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. Front Oncol. 2020;10:1325. doi:10.3389/fonc.2020.01325
- Lee BM, Chung SY, Chang JS, et al. The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy. Gut Liver. 2018;12(3):342–352. doi:10.5009/gnl17216
- Gao Y, Guo W, Cai S, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected esophageal squamous cell carcinoma. J Cancer. 2019;10(14):3188–3196. doi:10.7150/jca.30281
- Li N, Zhang Y, Qu W, et al. Analysis of systemic inflammatory and coagulation biomarkers in advanced cervical cancer: prognostic and predictive significance. Int J Biol Markers. 2023;38(2):133–138. doi:10.1177/03936155231163599
- He X, Wang M, Zhong WL. Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring. J Oncol. 2022;2022:1–6. doi:10.1155/2022/8800787
- Bergqvist M, Nordmark A, Williams A, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers. 2023;28(3):313–322. doi:10.1080/1354750X.2023.2168063
- Tribukait B, Lundgren PO, Kjellman A, et al. Prediction of Overall Survival by Thymidine Kinase 1 Combined with Prostate-Specific Antigen in Men with Prostate Cancer. Int J Mol Sci. 2023;24(6):5160. doi:10.3390/ijms24065160
- Costa Svedman F, Jalsenius M, Grozman V, et al. Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. Acta Oncol. 2022;61(9):1116–1120. doi:10.1080/0284186X.2022.2121615
- Buskwofie A, David-West G, Clare CA. A Review of Cervical Cancer: incidence and Disparities. J Natl Med Assoc. 2020;112(2):229–232. doi:10.1016/j.jnma.2020.03.002
- Vu M, Yu J, Awolude OA, et al. Cervical cancer worldwide. Curr Probl Cancer. 2018;42(5):457–465. doi:10.1016/j.currproblcancer.2018.06.003
- Cibula D, Dostálek L, Jarkovsky J, et al. Post-recurrence survival in patients with cervical cancer. Gynecol Oncol. 2022;164(2):362–369. doi:10.1016/j.ygyno.2021.12.018
- Chen G, He C, Li L, et al. Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix. BMC Cancer. 2013;13(1):249. doi:10.1186/1471-2407-13-249
- Zhu H. Squamous Cell Carcinoma Antigen: clinical Application and Research Status. Diagnostics. 2022;12(5):1065. doi:10.3390/diagnostics12051065
- Schepens EJA, Al-Mamgani A, Karssemakers LHE, van den Broek D, van den Brekel MWM, Lopez-Yurda M. Squamous Cell Carcinoma Antigen in the Follow-up of Patients With Head and Neck Cancer. Otolaryngol Head Neck Surg. 2023. doi:10.1002/ohn.510
- Volkova LV, Pashov AI, Omelchuk NN. Cervical Carcinoma: oncobiology and Biomarkers. Int J Mol Sci. 2021;22(22):12571. doi:10.3390/ijms222212571